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Introduction: Renal involvement is a severe complication in systemic lupus erythematosus (SLE). Moreover,
a subset of SLE patients develop the anti-phospholipid syndrome (APS), characterised by the occurrence of
anti-phospholipid antibodies in combination with macro- and microvascular thrombotic manifestations, including
acute and chronic antiphospholipid-associated nephropathy (APLN). Clinical presentations of lupus nephritis and
APLN are similar and a renal biopsy is necessary to differentiate between the conditions. Our aim with this study
was to investigate the occurrence of histopathological findings consistent with APLN (hAPLN) in renal biopsies
from SLE patients and to investigate associations with anti-phospholipid antibody specificities, clinical manifestations,
HLA-DRB1 alleles, and long-term renal outcome.
Method: Consecutive renal biopsies from 112 SLE patients with renal involvement were investigated and evaluated
for findings of hAPLN; in all there were 236 renal biopsies. Data from biopsy reports and clinical information were
collected. Autoantibodies against cardiolipin and β2-glycoprotein-1 were measured by enzyme-linked immunosorbent
assay. A lupus anticoagulant test was determined with a modified Dilute Russel Viper Venom method. HLA genotyping
was performed by sequence-specific primer PCR. Renal outcome was determined at study end.
Results: The prevalence of hAPLN was 14.3% among SLE patients with renal involvement. Compared to patients
with pure lupus nephritis, occurrence of hAPLN was associated with intima changes (odds ratio (OR) = 24; 95%
confidence interval (CI), 3.0 to 189.8; P < 0.0001), hypertensive vascular changes (OR = 7.8; 95% CI, 1.6 to 39.4;
P = 0.01), inflammatory infiltrates (OR = 6.5; 95% CI, 1.7 to 25.1; P = 0.007) and tubular atrophy (OR = 13.1; 95% CI,
1.7 to 103.6; P = 0.002). hAPLN was associated with the presence of cardiolipin antibodies (OR = 3.3; 95% CI, 1.0
to 10.8; P = 0.05) and triple anti-phospholipid antibody positivity (OR = 4.2; 95% CI, 1.3 to 13.7; P = 0.02). Patients
with hAPLN were more hypertensive (OR = 3.8; 95% CI, 1.2 to 12.3; P = 0.03) and had higher levels of creatinine
as compared to lupus nephritis patients (median 116 versus 75 μmol/L; P < 0.0001). We found significantly higher
frequency of HLA-DRB1*13 (OR = 5.1; 95% CI, 1.7 to 15.4; P = 0.03) and development of end-stage renal disease
(OR = 5.8; 95% CI, 1.7 to 19.7; P = 0.008) in hAPLN compared with lupus nephritis.
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Conclusion: hAPLN is a severe and often unrecognized condition in SLE patients with renal involvement. We have
demonstrated an increased risk for development of renal impairment and a genetic predisposition in hAPLN
patients compared to lupus nephritis patients.Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease characterized by a heterogeneous set of
clinical presentations including renal manifestations and
the presence of autoantibodies. Antiphospholipid anti-
bodies (aPL) are detected in 30 to 50% of patients with
SLE and are associated with thromboembolic complica-
tions. Lupus nephritis (LN) of varying severity affects
up to 60% of SLE patients [1,2]. Apart from the glom-
erular lesions seen in LN, patients with SLE may de-
velop renal microangiopathy which may be identical to
findings seen in patients with the antiphospholipid syn-
drome (APS) [3]. The microangiopathy can be acute or
chronic and may occur in isolation or with concurrent
LN [4-7]. Of note, the clinical presentations are similar
and a renal biopsy is required to distinguish APS-related
findings from pure LN.
In the most recent consensus criteria of APS [3], the
term antiphospholipid-associated nephropathy (APLN)
was suggested to describe the entity of aPL in associ-
ation with renal vasculopathy. In previous publications,
however, various definitions have been used to describe
the acute condition thrombotic microangiopathy (TMA)
[7], isolated renal microthrombi [5], or both acute and
chronic renal findings [4,6]. Thus, full comparisons be-
tween studies on renal vasculopathy in SLE populations
are difficult to perform. It is also of note that aPL have not
been identified in all cases with APLN in SLE [4,7] and
the natural history of APLN development over time is
largely unknown.
aPL are a family of autoantibodies which target mem-
brane structures such as phospholipids or phospholipid-
binding proteins. In clinical practice, aPL positivity is
determined by occurrence of anticardiolipin antibodies
(aCL) or of those to the protein co-factor β2-glycopro-
tein-1 (β2GP1) as measured by enzyme-linked immuno-
sorbent assay (ELISA), or positivity in the functional
lupus anticoagulant (LA) test. LA detects aPL, which are
capable of prolonging in vitro coagulation assays [3,8,9],
and has been shown to be more closely related to clinical
symptoms than positive ELISA tests [1,10]. With regard to
APLN, data have been divergent concerning the associa-
tions with different aPL [4-7].
There is a genetic predisposition to certain sub-
phenotypes of SLE, including nephritis [11,12]. Further-
more, variations in human leukocyte antigen (HLA)
genes have previously been found to associate with aPLin SLE [13]. We have recently demonstrated an associ-
ation between the development of both aPL and macro-
vascular thrombotic events among SLE patients with
the HLA-DRB1 alleles and with the polymorphism in
the signal transducer and activator of transcription fac-
tor 4 (STAT4) gene [12,14]. The STAT4 risk allele on
chromosome 2 was also recently demonstrated to be
associated with LN as well as with the development of
severe renal insufficiency, thus further indicating that
genetic predisposition is of importance for disease pro-
gression in LN [11]. No genetic studies on APLN were
known at the time of our investigation.
We have investigated the occurrence of histopatho-
logical renal microangiopathy in accordance with APLN
in consecutive biopsies from a large cohort of SLE pa-
tients with renal involvement. We chose to define the
renal vascular findings, regardless of antibody findings,
as histopathological APLN (hAPLN). We studied the renal
outcome in patients with hAPLN in comparison to pa-
tients with pure LN and investigated the occurrence of
hAPLN over time in repeated renal biopsies. Although
hAPLN has been associated with more severe renal dis-
ease in SLE [4-6], data on long-term outcome are still an
issue of concern and were therefore investigated in this
study. Finally, we studied the impact of HLA-DRB1 alleles
on the occurrence of hAPLN.
Methods
Patients
Consecutive renal biopsies performed between 1995 and
2011 in patients included in the Karolinska SLE Cohort
[12] were used in this study. All patients fulfilled at least
four classification criteria for SLE [15] and were recruited
from both the rheumatology and nephrology units in
order to obtain a representative selection with regard to
renal involvement. Information was collected from first
study biopsy until 31 December 2012. Patients with renal
findings that were not related to LN or hAPLN were not
included in the study. All patients had given informed
written consent to participate in the study and the study
protocol was reviewed and approved by the regional ethics
committee at Karolinska Institutet in Stockholm, Sweden.
Renal biopsies and clinical information
All renal biopsies were evaluated for findings in accord-
ance with hAPLN and/or LN. Simultaneously with the bi-
opsies, clinical and laboratory data including occurrence
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ulants, and antihypertensive medication were collected.
Hypertension was considered as present if patients were
diagnosed with and prescribed medications for high blood
pressure or if the patient had a blood pressure >140/90
mmHg at time of biopsy. Patients treated with angiotensin
converting enzyme inhibitors and/or angiotensin receptor
blockers for anti-proteinuric indications only were not
regarded as hypertensive.
Evaluation of renal biopsies
All biopsies were evaluated by one experienced patholo-
gist (BS) and examined with light microscopy, immuno-
fluorescence and electron microscopy. Glomerular lesions
were assessed according to World Health Organization
criteria [16] and/or the International Society of Nephrol-
ogy/Renal Pathology Society criteria [17] depending on
the date of biopsy. Information about vascular findings,
intima change, interstitial fibrosis, inflammatory infiltrates,
tubular atrophy and hypertonic vascular changes as well
as findings from electron microscopy were also extracted
from the pathology reports.
Vascular findings consistent with APLN [3] were re-
ported and further divided into acute TMA and chronic
hAPLN. TMA was defined as occurrence of fibrin thrombi
in arterioles and/or glomerular capillaries. Definition of
chronic features of hAPLN included presence of fibrous
intimal hyperplasia with or without recanalization, fibrous
and/or fibrocellular occlusions of arteries and arterioles
and focal cortical atrophy [4,6,18]. In cases where acute
TMA occurred without concomitant LN, other conditions
that may cause endothelial dysfunction were excluded be-
fore inclusion in the study. Cases in which a definite diag-
nosis of hAPLN was doubtful were re-assessed by the
pathologist for a definite diagnosis.
Laboratory data
Laboratory data were analysed at the time of the biopsy
and performed according to clinical routine. In this study
we included levels of creatinine (μmol/L), albumin (g/L)
and haemoglobin (g/L).
Autoantibodies
Autoantibodies were analyzed in the Department of Clin-
ical Immunology at the Karolinska University Hospital. For
aCL and anti-β2GP1 antibody detection, ELISA and multi-
plex methods were used. aCL was evaluated for both
immunoglobulin (Ig)G and IgM isotypes. For anti-β2GP1,
only the IgG isotype was measured. We also recorded if pa-
tients had a positive LA, determined with a modified Dilute
Russel Viper Venom method (Biopool, Umeå, Sweden).
Being a retrospective observational study (spanning
January 1995 to December 2012), methods for autoanti-
body detection have changed during the study period.Tabulated data were thus recorded as positive or nega-
tive according to the cut-off levels of the routine method
used at the time of analysis.
The data available in the Karolinska SLE Cohort in-
cluded current and retrospective information regarding
serological profile and occurrence of aCL and anti-β2GP-
1, as well as LA positivity. Autoantibody and LA positivity
was also determined at the time of renal biopsy. Autoanti-
body and/or LA positivity was thus determined both at
and before biopsy, which enables a confirmation of auto-
antibody findings as required to fulfil the classification cri-
teria for definite APS according to Miyakis and colleagues
[3]. Furthermore, we determined if the patients were ever
positive in all three aPL tests (aCL (IgM and IgG), anti-
β2gGP-1 (IgG) and LA). This combination is described by
Pengo and colleagues as triple positivity [19], and is asso-
ciated with a more severe prognosis.
Long-term follow-up
The renal function was estimated at last follow-up by the
Modified Diet in Renal Disease formula [20], and the pa-
tients were classified into chronic kidney disease classes 1
to 5 [21]. We defined the time the patient reached chronic
kidney disease class 5 as end-stage renal disease (ESRD).
HLA typing
Two-digit HLA-DRB1 genotyping for the HLA-DRB1-
gene was previously performed by sequence-specific pri-
mer PCR and was also used for the present study [12].
We studied the following HLA-DRB1 allelic groups:
DRB1*01, DRB1*03, DRB1*04, DRB1*07, DRB1*08, DRB
1*09, DRB1*10, DRB1*11, DRB1*12, DRB1*13, DRB1*14,
DRB1*15 and DRB1*16 using dominant model.
Statistics
Chi-squared test and Fisher’s exact test were used as
appropriate for statistical analysis of selected categorical
variables, which included vascular changes consistent
with hAPLN, presence of aCL, anti-β2GP1 autoantibodies,
positive tests for LA, and hypertension. Odds ratios (ORs)
were calculated from contingency tables assessing the risk
of co-appearance of selected variables. For variables
with statistical significance, 95% confidence intervals
(CIs) were calculated.
Skewed continuous variables were log transformed to
obtain a normal distribution. For quantitative variables,
such as creatinine, albumin and haemoglobin, analysis
of variance was used. Mean and extremes are given for
descriptive purposes. Bonferroni correction was per-
formed for multiple comparisons when tabulating HLA
genotypes.
For statistical analysis JMP-11 software (SAS institute,
NC, USA) was used. Statistical significance was accepted
at P < 0.05.
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General patient characteristics
The original study cohort consisted of 126 patients with
a diagnosis of SLE who had renal biopsy performed due
to signs of renal involvement. Fourteen patients were
excluded from the study due to histopathological find-
ings other than LN or hAPLN (seven with focal necro-
tizing vasculitis in the active or inactive phase, one with
IgA nephropathy, one with thin basal membranes, one
with tubulointerstitial nephritis in accordance with
Sjögren’s syndrome, and four with unspecific chronic le-
sions with no prior history/biopsy with LN). The final
study cohort thus consisted of 112 patients who had
been subject to 236 biopsies in total. The median num-
ber of biopsies per patient was 2 (range 1 to 7) and the
median age at first study biopsy was 38 years (range 18
to 84 years).
There were 89 females (79.5%) and 23 males (20.5%).
In all, 201 biopsies (85.2%) were from female patients
and 35 (14.8%) from male participants. Patient charac-
teristics are displayed in Table 1.Table 1 Clinical characteristics in all patients at first study bio
All patients
(n = 112)
Median age (years (range)) 38 (18-84)
Male/female 23/89
Serum creatinine (μmol/L; median) 77
Serum albumin (g/L; median) 29
Haemoglobin (g/L; median) 113
Hypertension (n (%)) 41 (37)
Systolic blood pressure (mmHg; median) 125





Single positive aPL 36 (32)
Double positive aPL 9 (8)
Triple positive aPL 18 (16)
Definite APS 13 (12)
Treatment (n (%))




*Previous findings and/or at renal biopsy. P values are the comparison between the
Single positive, double positive and triple positive refers to autoantibody findings a
anticardiopin antibodies; anti-β2GP1, anti-β2-glycoprotein-1; APS, antiphospholipid s
histopathological antiphospholipid-associated nephropathy; LA, lupus anticoagulanRenal biopsies
Overall, 16/112 patients (14.3%) had findings in accordance
with hAPLN in at least one biopsy. Among all biopsies,
hAPLN was detected in 20/236 (8.5%). Thus, four patients
had two biopsies with hAPLN findings. Ten biopsies re-
vealed findings of LN with concomitant findings of hAPLN
while 10 had pure hAPLN. Of 236 biopsies, 226 (95.8%)
had changes compatible with LN according to either the
World Health Organization [16] or International Society of
Nephrology/Renal Pathology Society criteria [17].
Of the sixteen hAPLN patients, seven (43.8%) had
findings in their first study biopsy while 9/16 (56.2%) pa-
tients developed hAPLN following an initial diagnosis of
LN (median 8.3 years, range 1 to 28 years) from first bi-
opsy. Conversely, in three cases hAPLN was seen in the
first study biopsy, but not in a repeated biopsy. In the
hAPLN group, 4/20 (20%) biopsies were consistent with
the acute setting (TMA), while the majority 16/20 (80%)
had a more chronic phase of hAPLN.
For statistical purposes, when comparing clinical/labora-
tory variables in the LN group (n = 96) versus the hAPLNpsy
LN hAPLN* P value
(n = 96) (n = 16)





30 (31) 11 (69) 0.03
120 137 0.01
80 80 0.1
46 (48) 12 (75) 0.05
17 (18) 6 (38) 0.07
21 (22) 7 (44) 0.06
31 (32) 5 (31) 0.9
8 (8) 1 (6) 0.8
12 (13) 6 (38) 0.02
10 (10) 3 (19) 0.3
8 (0-40) 15 (0-60) 0.006
29 (30) 11 (69) 0.007
7 (7) 3 (19) 0.2
13 (14) 3 (19) 0.7
two diagnostic groups (LN/hAPLN). Values in bold are significant at <0.05.
t or before biopsy. ACEi, angiotensin converting enzyme inhibitor; aCL,
yndrome; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; hAPLN,
t; LN, lupus nephritis.
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opsy in the LN patients and the first biopsy demonstrating
hAPLN findings in the hAPLN group. Thus, nine patients
with initial LN were included in the LN group and data
from the first hAPLN biopsy was used for comparison
between the groups. No association between age or gen-
der comparing the LN and hAPLN groups was found.
Data on all biopsy findings in the hAPLN patients are
shown in Table 2.
Histopathology
We extracted the histopathological findings available in
biopsy reports from all patients. Compared to the LN
group, hAPLN patients were associated with occurrence
of hypertensive vascular changes (P = 0.01), inflammatory
infiltrates (P = 0.007), interstitial fibrosis (P = 0.02), intima
changes (P < 0.0001), and tubular atrophy (P = 0.002).
We found that all hAPLN biopsies without LN find-
ings (n = 10) had inflammatory changes. In contrast, of
the patients with hAPLN and concomitant LN 5 hadTable 2 Histopathological classification*, age and developme





1 - - hAPLN
2 II (36) - hAPLN
3 - - hAPLN
4 hAPLN (8) - hAPLN




6 IV (26) V (35) hAPLN
IV (28)
III (29)
7 - II (40) hAPLN
8 - II (27) hAPLN
9 - III (25) hAPLN




11 II + V (24) - hAPLN
12 - - hAPLN
13 - - hAPLN
14 - - hAPLN
15 - - hAPLN
16 V (56) - hAPLN
*Class II, III, IV and V refers to either the World Health Organization [16] or Internati
lupus nephritis, histopathological antiphospholipid-associated nephropathy (hAPLNinflammatory changes while the remaining 5 had no
signs of inflammation (data not shown).
The histopathological findings are shown in Table 3.
Routine laboratories
In all 112 patients, the median serum creatinine was 77
μmol/L (mean 98, range 39 to 514) at first study biopsy.
Serum creatinine levels were higher in the hAPLN
group (median 116) as compared to the LN group (me-
dian 75; P < 0.0001). Albumin and haemoglobin levels
did not differ between the hAPLN and LN groups as
shown in Table 1.
Blood pressure
Twenty-seven patients (24.2%) had a diagnosis of, and
received treatment for, hypertension at first study
biopsy. Of these, nine also had vascular changes con-
sistent with hAPLN. There was a positive association
between hAPLN and hypertension (OR = 3.8; 95% CI,
1.2 to 12.3; P = 0.03).nt of end-stage renal disease in hAPLN patients
I (age) Biopsy II (age) Biopsy III (age) ESRD (age)
(54) - - -
/IV (38) II (39) V (41) + (55)
(49) hAPLN (53) - -
/II (28) - - + (28)
(47) - - -
/V (36) - - -
/V (43) - - -
(29) Scarring (29) hAPLN (34) + (38)
/II (26) - - -
/V (27) V (33) - -
/II + V (52) - - -
/V (30) hAPLN/V (33) - + (36)
/V (58) V (59) - -
(61) - - -
(55) hAPLN (58) - + (58)
(62) - - + (66)
onal Society of Nephrology/Renal Pathology Society [17] classification criteria of
) and end-stage renal disease (ESRD).
Table 3 Histopathological findings in the study cohort
All patients LN hAPLN P value
(n = 112) (n = 96) (n = 16)
Hypertensive vascular
changes
37 (33) 29 (30) 8 (50) 0.01
Inflammatory infiltrates 41 (37) 30 (31) 11 (69) 0.007
Interstitial fibrosis 82 (73) 67 (70) 15 (94) 0.02
Intima changes 50 (45) 35 (37) 15 (94) <0.0001
Tubular atrophy 63 (56) 48 (50) 15 (94) 0.002
Values are shown as n (%). P values are comparisons between the two
diagnostic groups: lupus nephritis (LN) and histopathological
antiphospholipid-associated nephropathy (hAPLN).
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125 mmHg (range 90 to 190 mmHg) and the median
diastolic blood pressure at biopsy was 80 mmHg (range
55 to 110 mmHg). Systolic blood pressure was higher in
hAPLN patients (median 137 mmHg, range 100 to 190
mmHg) as compared to LN patients (median 120 mmHg,
range 90 to 190 mmHg; P = 0.01), but no difference was
found when comparing diastolic blood pressure. Results
are shown in Table 1.
Antiphospholipid antibodies and lupus anticoagulant
In all patients, 58 (52%) tested positive for aCL, 23 (21%)
for anti-β2GP1 and 28 (25%) for LA at and/or prior to
first study biopsy.
Of the patients in the LN group, 46 (48%) tested positive
for aCL, 17 (18%) for anti-β2GP1 and 21 (22%) for LA.
Among the hAPLN patients, 12 (75%) tested positive
for aCL, 6 (38%) for anti-β2GP1 and 7 (44%) for LA. Data
on antibodies and LA are presented in Table 1.
hAPLN was positively associated with the presence of
aCL (OR = 3.3; 95% CI, 1.0 to 10.8; P = 0.05). Although
the association between hAPLN and anti-β2GP1 or LA
(P = 0.07 and P = 0.06, respectively) did not reach statis-
tical significance, the combinations between all three tests
(triple positivity, as defined by Pengo and colleagues [19])
was increased in the hAPLN patients compared to the LN
group (OR = 4.2; 95% CI, 1.29 to 13.65; P = 0.02).
Treatment at time of first renal biopsy
Oral prednisolone was prescribed to 76 (67.8%) patients.
The median dosage in all patients at the time of biopsy
was 8 mg/day (mean 11 mg/day, range 0 to 60 mg/day).
The median dosage in the hAPLN group was 15 mg/day
and in the LN group was 8 mg/day (P = 0.006). The num-
ber of patients receiving angiotensin converting enzyme
inhibitors and/or angiotensin receptor blockers, acetylsali-
cylic acid, and warfarin are shown in Table 1.
Outcome at last follow-up
Development of ESRD was seen in 15 patients, compris-
ing 9/96 (9.4%) in the LN group and 6/16 (37.5%) in thehAPLN group (OR = 5.8; 95% CI, 1.7 to 19.7; P = 0.008).
The mean time to development of ESRD was 4.4 years
following first study biopsy (3.4 years for LN, and 5.9
years for hAPLN).
HLA-DRB1 allotypes
Patients with hAPLN were more likely to carry the HLA-
DRB1*13 allele in comparison to LN patients (OR = 5.1;
95% CI, 1.7 to 15.4; P = 0.03 after Bon Ferroni correction).
There were no differences between hAPLN and LN for
HLA-DRB1*01, *03, *04, *07, *08, *09, *10, *11, *12, *14,
*15 or *16 allotypes. Results shown in Table 4.
Discussion
We detected renal microvascular changes in accordance
with hAPLN in 14.3% of the patients in a large cohort of
SLE patients with biopsy-proven renal involvement.
Overall, hAPLN patients presented with more hyperten-
sion, severe histopathology and impaired renal function
when compared to patients with pure LN. hAPLN was
associated with aCL and with triple aPL positivity. Fur-
thermore, the HLA-DRB1*13 allele was associated with
hAPLN in the investigated patients. Our results thus in-
dicate for the first time that a genetic predisposition may
contribute to hAPLN in SLE.
In previous studies, at least one histological lesion
compatible with hAPLN, either as isolated findings or
in addition to LN, was seen in 24 to 32% of patients
with SLE [6,7]. Zheng and colleagues [5] detected glom-
erular microthrombi in 20% of LN patients, which was
associated with poorer renal function as well as more
severe renal tissue injury. In our study, the observed
prevalence of hAPLN was somewhat lower compared to
previous studies. Differences in definitions, varying study
populations, and indication for renal biopsy are likely to
contribute to the observed differences in prevalence. Of
note, our study included mainly Caucasian patients as op-
posed to the Asian population included in previous studies
[5,7] and ethical differences could also have contributed.
It has previously been proposed that outer folded or
wrinkled basement membrane may be characteristic of
microangiopathy in association with APS [22]. However,
in the hAPLN group this was only detected in one of the
patients (data not shown). Thus, electron microscopy
evaluation did not seem to add diagnostic value.
We found a higher proportion of inflammatory infil-
trates in the hAPLN group compared to the LN group.
In cases with concomitant LN and hAPLN, it was not
possible to determine whether the inflammatory infil-
trates were caused by either condition. The striking find-
ing of inflammation in the pure hAPLN group, however,
strongly indicates that circulatory causes (for example,
ischaemia caused by hAPLN or hypertension) have con-
tributed to occurrence of the inflammatory infiltrates.
Table 4 HLA-DRB1 alleles and association with hAPLN




value(n = 110*) (n = 94) (n = 16)
*01 16 (15) 16 (17) 0 (0) NS 0.1
*03 43 (39) 36 (38) 7 (44) NS 0.7
*04 23 (21) 20 (21) 3 (19) NS NS
*07 12 (11) 11 (12) 1 (6) NS NS
*08 7 (6) 6 (6) 1 (6) NS NS
*09 4 (4) 4 (4) 0 (0) NS NS
*10 3 (3) 2 (2) 1 (6) NS 0.4
*11 11 (10) 11 (12) 0 (0) NS 0.4
*12 4 (4) 4 (4) 0 (0) NS NS
*13 28 (26) 19 (20) 9 (56) 0.03 0.002
*14 4 (4) 3 (3) 1 (6) NS 0.5
*15 49 (45) 44 (47) 5 (31) NS 0.3
*16 3 (3) 2 (2) 1 (6) NS 0.4
Values are shown as n (%). P values are comparisons between the two diagnostic groups: lupus nephritis (LN) and histopathological antiphospholipid-associated
nephropathy (hAPLN). NS, not significant.
*Genetic analysis had not been performed on two of the patients.
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biopsies could also be due to the large number of re-
peated biopsies in the study cohort. However, the re-
peated biopsies available gave us a unique opportunity
to study the natural history of hAPLN, its development
and disappearance. Of note is that, in three of the patients
with hAPLN, all findings had disappeared at re-biopsy.
Interestingly, this implies that hAPLN can be transient, or
possibly focal. Another important observation is that 56%
of hAPLN appeared de novo in patients who had previ-
ously had pure LN. Taken together, these observations
demonstrate that repeated biopsies are important when
the clinical course indicates an unexplained deterior-
ation of renal function, especially in patients who are
aPL positive.
We found that hAPLN was associated with aCL, but a
strong trend between hAPLN and anti-β2GP1 or LA was
also detected. The lack of statistical significance for anti-
β2gGP1 and LA was most likely due to the sample size.
Consistent with our findings, Tektonidou and colleagues
[4] reported an association between APLN and aCL, but
also with LA. On the other hand Daugas and colleagues
[6] demonstrated a strong association between APLN
and LA, but not between APLN and aCL. In a study on
occurrence of glomerular microthrombi, there was a
strong association with LA and anti-β2GP1, but not with
aCL [5]. The divergent aPL associations previously re-
ported are likely to be due to methodological issues, as dif-
ferent assays for aPL and LA detection have been used
and cut-off values have varied between studies.
The strong association of hAPLN with aCL is consist-
ent with APLN being a manifestation of APS [3]. It is,however, also important to note that 25% of patients with
renal findings in accordance with hAPLN had no detect-
able aPL at all using the assays available at the time. Simi-
lar findings have previously been reported [4,7].
It has previously been shown that patients suffering
from SLE and systemic hypertension have a worse prog-
nosis concerning renal survival as compared to normo-
tensive individuals [23]. Furthermore, we have previously
demonstrated that aPL in SLE patients is a risk factor for
cardiovascular disease [24] and both aPL and loss of renal
function predicted mortality in SLE [25]. In the present
study there was a clear association between hAPLN and
hypertension. The hAPLN group was also associated with
higher creatinine levels, which is in line with previous
publications [4-6]. In addition, we could demonstrate that
hAPLN was associated with more severe histopathological
renal findings as well as with development of ESRD in
long-term follow-up. Considering both previous find-
ings and the present results, there are strong indications
that patients with hAPLN belong to a high-risk SLE
sub-group. Adequate follow-up and antihypertensive ther-
apy are likely to prevent impairment of renal function, but
this should ideally be studied in prospective studies. As a
first step towards the performance of prospective treat-
ment studies on patients with APLN, it is also important
to reach an international consensus regarding the defin-
ition of APLN.
Associations between aPL and the HLA-DRB1*04 allele
were reported be Galeazzi and colleagues [13]. We re-
cently demonstrated that the HLA-DRB1*04 and HLA-
DRB1*13 alleles alone and in particular the combination
of these two alleles (HLA-DRB1*04/*13) were associated
Gerhardsson et al. Arthritis Research & Therapy  (2015) 17:109 Page 8 of 9both with aPL of several specificities and with an in-
creased risk of macrovascular events among SLE pa-
tients [12]. In this study, we extend these observations
by demonstrating that microvascular lesions in the kid-
ney are also associated with HLA-DRB1*13. Thus, a
similar genetic factor may confer risk of aPL-associated
disease in SLE.
The large consecutive sample size, also including re-
peated biopsies, gave us a unique opportunity to study
the prevalence and natural history of hAPLN in SLE pa-
tients. Due to retrospective data collection, and lack of
repeated measurements of aPL in some cases, we were,
however, not able to fully define occurrence of APS.
Somewhat surprisingly, hAPLN patients had higher
doses of prednisone at biopsy compared to LN individ-
uals. This could be explained by the more severe pheno-
type with higher creatinine thus requiring more intense
treatment, but the high steroid usage could also have
contributed to the more pronounced hypertension seen.
However, the more extensive use of corticosteroids,
which is unlikely to affect hAPLN findings in general,
point to the importance of performing renal biopsies in
order to optimize treatment strategies and avoid over-
treatment with corticosteroids and immunosuppressants.
Currently there are no consensus guidelines for treat-
ment of APLN, but it is generally recommended that pa-
tients should receive anti-hypertensive and anticoagulative
treatments. Considering the associated risk for impaired
renal function, randomized trials are urgently needed to
explore optimal treatment regimens in order to preserve
renal function in this sub-group of SLE patients.Conclusion
In conclusion, our results demonstrate that hAPLN is a
severe, but not uncommon, finding in lupus patients with
renal involvement. The association between renal path-
ology and occurrence of aPL indicates that hAPLN is a
separate renal disease entity with different underlying
pathogenic mechanisms compared to LN. Due to the
increased risk of renal impairment, vasculopathies in LN
require an increased awareness. Genetic findings may con-
tribute to hAPLN.
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